Interferon-gamma, Recombinant

Phase 3Small molecule

RRadboud University Medical Center

Interferon-gamma, Recombinant is one of 29 small molecule programs targeting Paralysis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParalysisActive, not recruiting

CandidemiaActive, not recruiting

ParalysisPhase 3

Active, not recruiting

CandidemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Paralysis

#DrugCompanyPhaseTrials

Prostigmin

Merck & Co.

Approved

3 2

Robinul

Alnylam Pharmaceuticals

Approved

1 3

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

3 4

Movantik

AAveritas Pharma, Inc.

Approved

1 5

Naropin

FFresenius Kabi Oncology Ltd.

Approved

1 6

Relistor

SSalix

Approved

1 7

Dulcolax

Boehringer Ingelheim

Approved

1 8

Polyethylene Glycols

JJinnah Postgraduate Medical Centre

Approved

1 9

Minocin

TTriax

Phase 3

1 10

Senna

MMedtronic - MITG

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Candidemia1 trial

Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia

Unknown status·RRadboud University Medical Center·Phase 3·NCT01270490·20 enrolled

Paralysis1 trial

The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis

Completed·RRadboud University Medical Center·Phase 3·NCT01649921·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Interferon-gamma, Recombinant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interferon-gamma, Recombinant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interferon-gamma, Recombinant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRadboud University Medical Center

Interferon-gamma, Recombinant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Candidemia1 trial

Paralysis1 trial

References

Drug Info

Quick Facts

Related News